Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Plaque Psoriasis AND Plaque Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    228 result(s) found for: Chronic Plaque Psoriasis AND Plaque Psoriasis. Displaying page 11 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2014-002056-40 Sponsor Protocol Number: DIA2014-1 Start Date*: 2014-08-12
    Sponsor Name:Diakonhjemmet Hospital AS
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVAT...
    Medical condition: Rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    18.0 100000004858 10071117 Plaque psoriasis LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    18.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    18.0 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003697-14 Sponsor Protocol Number: PsoPET2 Start Date*: 2017-12-18
    Sponsor Name:Aarhus University Hospital
    Full Title: A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-sever...
    Medical condition: Moderate-to-severe psoriasis. Vascular and systemic (splenic) inflammation in psoriasis subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    20.0 100000004866 10003605 Atherosclerosis of aorta LLT
    20.0 100000004851 10041634 Spleen disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005097-10 Sponsor Protocol Number: IM011-054 Start Date*: 2021-08-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Diseas...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000175-16 Sponsor Protocol Number: AVXCLIN004 Start Date*: 2019-04-24
    Sponsor Name:Avexxin AS
    Full Title: A Phase IIa, Randomized, Vehicle- and Comparator-Controlled, Double-Blind for the IMPs, Observer-Blind for the Comparator Trial to Evaluate the Safety and Antipsoriatic Efficacy of AVX001 in a Psor...
    Medical condition: Chronic psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004504-33 Sponsor Protocol Number: BAT-2206-002-CR Start Date*: 2021-07-20
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003078-28 Sponsor Protocol Number: 1368-0016 Start Date*: 2019-07-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to ...
    Medical condition: Palmoplantar Pustulosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10050185 Palmoplantar pustulosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-005848-87 Sponsor Protocol Number: 250708BS (CRx-191-001) Start Date*: 2007-10-08
    Sponsor Name:CombinatoRx, Inc.
    Full Title: A single-center, randomized, double-blind, vehicle-controlled study to assess the activity of CRx-191 in reducing the psoriatic infiltrate band thickness in plaque psoriasis.
    Medical condition: Plaque psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017272-24 Sponsor Protocol Number: P05495 Start Date*: 2011-01-10
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Completed) GB (Completed) FI (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-004740-51 Sponsor Protocol Number: 240213BS Start Date*: 2005-08-15
    Sponsor Name:Agis Industries (1983) ltd.
    Full Title: Determination of antipsoriatic efficacy of topical paroxetine hydrochloride ointments in a psoriasis plaque test
    Medical condition: healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002608-15 Sponsor Protocol Number: CC-10004-PSOR-025 Start Date*: 2019-04-03
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis
    Medical condition: MODERATE TO SEVERE GENITAL PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10063407 Psoriasis genital LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005036-26 Sponsor Protocol Number: FXT-05 Start Date*: 2011-11-29
    Sponsor Name:Funxional Therapeutics Ltd
    Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease
    Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004241-16 Sponsor Protocol Number: B7931030 Start Date*: 2019-08-02
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORI...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) BG (Completed) LT (Completed) EE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003600-23 Sponsor Protocol Number: APRICOT Start Date*: 2016-04-01
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies
    Medical condition: Acral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005099-36 Sponsor Protocol Number: IM011-055 Start Date*: 2021-08-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Completed) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019941-24 Sponsor Protocol Number: CC-10004-PSA-004 Start Date*: 2010-12-01
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that, depending on the method of ascertainment, occurs in 6 to 39% of patients with psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) SK (Completed) FI (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005888-52 Sponsor Protocol Number: 4858-202 Start Date*: 2022-04-13
    Sponsor Name:Nimbus Lakshmi, Inc.
    Full Title: A Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-003050-96 Sponsor Protocol Number: 04EU/BMT06 Start Date*: 2005-12-02
    Sponsor Name:IBSA
    Full Title: Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for ...
    Medical condition: chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033898 Parapsoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001770-59 Sponsor Protocol Number: BAT-2306-002-CR Start Date*: 2022-10-19
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000707-34 Sponsor Protocol Number: 2316 Start Date*: 2011-11-08
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Trust
    Full Title: The induction of apoptosis by anti-psoriatic treatments
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 07:07:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA